WebMD Health Corp. : Continuation of the bullish trend
Entry price | Target | Stop-loss | Potential |
---|
US$46.36 |
US$50 |
US$45 |
+7.85% |
---|
The share WebMD Health, a US company providing information services in the field of consumer health for professionals remains interesting with growth of 16% since the beginning of the year.
The company has strong fundamentals. Sales are expected for 2015, up 9% to USD 632 million. In addition, the Thomson Reuters consensus revised upward earnings per share for the current fiscal year. The latter estimate is expected in 2015 to USD 1.45 up 45% compared to the previous year.
From a technical point of view, the stock operates in an upward trend for several weeks. Moreover, the positive orientation of moving averages doesn't suggest a reversal trend in the coming sessions. This growth is expected to quickly reach the USD 47.8 resistance and by extension new bullish targets.
Thus, taking into account the good fundamentals and the interesting technical configuration, it seems appropriate to open a long position in WebMD Health in this current area to enjoy the rebound. The first goal is attached to the medium-term USD 47.8 resistance and then above this level, opens new bullish targets. A stop loss is placed below the oblique at USD 45, threshold that would invalidate the strategy.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.